Bardhan Mainak, Anand Ayush, Javed Amaan, Chilo Maria Andrea, Khan Nida, Garg Tulika, Surana Arihant, Huang Helen, Samim M M, Suresh Vinay, Khare Abhinav, Menon Bindu, Kundu Tithishri
The John P. Hussman Institute for Human Genomics, Miller School of Medicine, University of Miami, Miami, FL 33101, USA.
The Dr. John T. Macdonald Foundation, Department of Human Genetics, Miller School of Medicine, University of Miami, Miami, FL 33101, USA.
Diseases. 2025 Sep 16;13(9):305. doi: 10.3390/diseases13090305.
Melanocortin receptors (MCRs) are responsible for various functions ranging from skin pigmentation, regulation of appetite, stress response and cognition, steroid synthesis, and energy balance to cellular regeneration and immunomodulation. The genetic polymorphism with tissue distribution ranging from the brain, limbic system, and adrenal cortex to neutrophils, monocytes, and macrophages is evident in MCRs. The mutations in MC1R, MC2R, MC3R, and MC4R genes are associated with risk of melanoma, familial glucocorticoid deficiency, obesity, and type 2 diabetes mellitus, respectively. Meanwhile, MC1R, MC2R, and MC5R genes are involved in the risk of major depressive disorder. Melanocortin receptors are involved in different inflammatory disorders, i.e., atopic dermatitis, autoimmune uveitis, sarcoidosis, respiratory diseases, multiple sclerosis, scleroderma, inflammatory bowel disease, amyotrophic lateral sclerosis, Alzheimer's disease, arthritis, and reperfusion injury. Several newer therapeutic agents related to MCRs have numerous advantages over the current anti-inflammatory drugs, demonstrating therapeutic relevance. Among them, α-MSH analogs play a role in atopic dermatitis and scleroderma, and MC1R agonist Dersimelagon has shown effectiveness in systemic sclerosis. The FDA has recently approved the repository corticotropin injection (RCI) to treat sarcoidosis. The FDA has also approved various melanocortin agonists, i.e., Bremelanotide, Afamelanotide, and Setmelanotide, for the treatment of hypoactive sexual desire disorder, Erythropoietic protoporphyria, and obesity, due to pro-opiomelanocortin and leptin receptor deficiency, respectively. Therefore, this review aims to summarize the function and genetic polymorphism of melanocortin receptors, regulatory pathways involving MCRs, and the existing evidence of the prime effect of MCRs on inflammatory responses via different mechanisms and their potential therapeutic use in inflammatory diseases.
黑皮质素受体(MCRs)负责多种功能,从皮肤色素沉着、食欲调节、应激反应和认知、类固醇合成、能量平衡到细胞再生和免疫调节。MCRs存在明显的基因多态性,其组织分布范围从大脑、边缘系统、肾上腺皮质到中性粒细胞、单核细胞和巨噬细胞。MC1R、MC2R、MC3R和MC4R基因的突变分别与黑色素瘤、家族性糖皮质激素缺乏症、肥胖症和2型糖尿病的风险相关。同时,MC1R、MC2R和MC5R基因与重度抑郁症的风险有关。黑皮质素受体参与不同的炎症性疾病,即特应性皮炎、自身免疫性葡萄膜炎、结节病、呼吸系统疾病、多发性硬化症、硬皮病、炎症性肠病、肌萎缩侧索硬化症、阿尔茨海默病、关节炎和再灌注损伤。几种与MCRs相关的新型治疗药物相对于目前的抗炎药物具有许多优势,显示出治疗相关性。其中,α-MSH类似物在特应性皮炎和硬皮病中起作用,MC1R激动剂Dersimelagon在系统性硬化症中已显示出有效性。美国食品药品监督管理局(FDA)最近批准了促肾上腺皮质激素注射剂(RCI)用于治疗结节病。FDA还分别批准了各种黑皮质素激动剂,即布雷美拉诺肽、阿法美拉诺肽和司美格鲁肽,用于治疗性欲减退症、红细胞生成性原卟啉症和肥胖症,分别是由于阿片促黑素皮质素原和瘦素受体缺乏所致。因此,本综述旨在总结黑皮质素受体的功能和基因多态性、涉及MCRs的调节途径,以及MCRs通过不同机制对炎症反应的主要作用的现有证据及其在炎症性疾病中的潜在治疗用途。